Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jan;64(2):240-55.
doi: 10.1111/j.1742-1241.2009.02254.x. Epub 2009 Nov 9.

Safety of Sildenafil Citrate: Review of 67 Double-Blind Placebo-Controlled Trials and the Postmarketing Safety Database

Affiliations
Free PMC article
Review

Safety of Sildenafil Citrate: Review of 67 Double-Blind Placebo-Controlled Trials and the Postmarketing Safety Database

F Giuliano et al. Int J Clin Pract. .
Free PMC article

Abstract

Aim: To review special safety topics associated with sildenafil and to document the tolerability of 50- and 100-mg doses, overall and by age, in men with erectile dysfunction (ED).

Methods: Data were collated from 67 double-blind placebo-controlled (DBPC) trials (> 14,000 men) conducted by the manufacturer and from the manufacturer's postmarketing safety database (39,277 patients). The DBPC data were stratified by dose, starting dose and age (> or = 65 and > or = 75 years). Special safety topics included cardiovascular risk, priapism, non-arteritic anterior ischaemic optic neuropathy (NAION), impaired renal and hepatic function, drug interactions (i.e. nitrates, cytochrome P3A4 inhibitors, other ED therapies and alpha-blockers) and incorrect use.

Results: Sildenafil was well tolerated at a dose of 50 or 100 mg in men with ED, overall, in those aged > or = 65 years, and in those aged > or = 75 years. Analyses of the databases did not reveal any causal link between sildenafil and cardiovascular events, or any new safety risks relating to cardiovascular events, priapism, NAION, hearing loss or drug interactions. In the small number of men with moderate impairment of renal function or hepatic function who were treated with sildenafil in DBPC trials, the safety profile was similar to that in men with no impairment of renal or hepatic function. Overdose with sildenafil was rare in the ED population. No new safety issues, emerging trends or adverse reactions were identified in conjunction with overdose, dependence, abuse or misuse.

Conclusion: This collated review confirms generally the good tolerability and established safety profile of sildenafil 50 and 100 mg in men with ED and reveals no new safety issues.

Figures

Figure 1
Figure 1
Rate of treatment-related adverse events over time collated from 17 randomised, double-blind, placebo-controlled, flexible-dose trials (sildenafil 25–100 mg, n = 2362; placebo, n = 1986). Treatment periods of up to 4 months were divided into 2-week intervals; the number of patients who experienced any adverse event was recorded for each interval and divided by the total number of patients who received treatment during that interval (38)

Comment in

Similar articles

See all similar articles

Cited by 26 articles

See all "Cited by" articles

References

    1. DinAlpha XR WW, Hodges M, Hargreaves C, et al. Sildenafil citrate (VIAGRA) in erectile dysfunction: near normalization in men with broad-spectrum erectile dysfunction compared with age-matched healthy control subjects. Urology. 1999;53:800–5. - PubMed
    1. Montorsi F, McDermott TED, Morgan R, et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies. Urology. 1999;53:1011–8. - PubMed
    1. Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med. 1998;338:1397–404. - PubMed
    1. Becher E, Tejada Noriega A, Gomez R, Decia R. Sildenafil citrate (Viagra) in the treatment of men with erectile dysfunction in southern Latin America: a double-blind, randomized, placebo-controlled, parallel-group, multicenter, flexible-dose escalation study. Int J Impot Res. 2002;14(Suppl. 2):S33–41. - PubMed
    1. Glina S, Bertero E, Claro J, et al. Efficacy and safety of flexible-dose oral sildenafil citrate (Viagra) in the treatment of erectile dysfunction in Brazilian and Mexican men. Int J Impot Res. 2002;14(Suppl. 2):S27–32. - PubMed

Publication types

MeSH terms

Feedback